Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
News Release
The Prognosis For Puma Biotechnology (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Alan H. Auerbach - Los Angeles Business Journal
Puma Biotechnology (Nasdaq:PBYI) - Stock Price, News & Analysis - Simply Wall St
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology Surging
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Can Puma Biotechnology Inc (PBYI) Stock Rise to the Top of Healthcare Sector Tuesday?
Puma Biotechnology Inc
PumaBiotech on Twitter: "Puma Biotechnology is dedicated to developing innovative, new treatments to help #cancer patients. As part of our ongoing commitment to the cancer community, we're proud to have participated in #
Puma Biotechnology - Updates, News, Events, Signals & Triggers
Puma Biotechnology falls more than 20%
